The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

Bristol Myers Squibb leapt into the drug industry’s most intense new rivalry on Monday, signing a deal to potentially spend ...

Merck MRK announced encouraging data from the dose confirmation portion of the phase II/III waveLINE-003 study evaluating its ...

The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Merck’s combo of KEYTRUDA and Trodelvy reduces disease progression or death risk by 35% in tough-to-treat breast cancer.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...